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Effect of nucleos(t)ide analogues therapy on HBsAg, intrahepatic HBV DNA and 
covalently closed circular DNA levels 
 
Danny Wong, Wai-Kay Seto, James Fung, Fung-Yu Huang, Ching-Lung Lai, Man-Fung 
Yuen 
The University of Hong Kong 
BACKGROUND: We aimed to study 1) the effects of 1-year nucleos(t)ide analogue (NA) 
therapy on HBsAg and covalently closed circular DNA (cccDNA) levels; and 2) the 
possible use of HBsAg reduction as a marker for cccDNA reduction. METHODS: We 
recruited 124 NA-treated patients with baseline and 1-year sera and liver biopsies. The 
NAs were categorized into the more potent (entecavir, telbivudine, and clevudine; n = 71) 
and less potent groups (lamivudine and adefovir; n = 53). cccDNA and HBsAg levels 
were measured by real-time PCR and the Elecsys HBsAg assay, respectively. RESULTS: 
At year 1, there were approximately 5 log(IU/ml), 2 log(copies/cell), and 1 
log(copies/cell) reductions in serum HBV DNA, intrahepatic total HBV DNA, and 
cccDNA, respectively. Only a small reduction of HBsAg (mean: 0.18 log[IU/ml]) was 
observed. There were no significant differences between the more and less potent NAs in 
the reduction of HBsAg, intrahepatic total HBV DNA and cccDNA. Although 88/124 
(71%) patients had undetectable serum HBV DNA, all had detectable HBsAg and 
intrahepatic total HBV DNA. Logarithmic reductions of HBsAg and cccDNA correlated 
weakly (r = 0.183, p = 0.042). Patients with cccDNA reduction. CONCLUSIONS: 
Despite the profound serum HBV DNA reduction after 1 year of therapy, reduction in 
HBsAg level was minimal, and reduction in intrahepatic total HBV DNA and cccDNA 
was relatively mild. HBsAg reduction may be a potential marker for the monitoring of 
cccDNA reduction during NA therapy. 
